Transaction in Own Shares

Summary by AI ^BETAClose X

Fevertree Drinks plc has announced the purchase of 207,061 ordinary shares between June 22nd and June 26th, 2026, as part of its share buyback program. The volume-weighted average price for these purchases ranged from 794.39p to 818.97p, with the lowest price per share at 785.00p and the highest at 831.50p. The company intends to cancel these repurchased shares.

Disclaimer*

Fevertree Drinks PLC

30 June 2026

30^th June 2026

Fevertree Drinks plc

("Fever-Tree" or the "Company")

Transaction in Own Shares

Fevertree Drinks plc ("Fever-Tree" or the "Company") announces today it has, in accordance with the authority granted by shareholders at its 2025 Annual General Meeting held on 5^th June, purchased the following number of ordinary shares of £0.0025 each in the Company (the "Ordinary Shares") through the Company's broker, Investec Bank plc ("Investec") in the period from 22^nd June to 26^th June 2026.

Date	Venue	Volume-weighted average price (p)	Aggregated volume	Lowest price per share (p)	Highest price per share (p)
22 June 2026	AIMX	795.0000	11,000	795.0000	795.0000
22 June 2026	XLON	796.8308	31,939	790.0000	805.5000
23 June 2026	AIMX	796.0000	15,000	796.0000	796.0000
23 June 2026	XLON	794.3906	28,113	786.0000	801.0000
24 June 2026	AIMX	813.0000	15,000	813.0000	813.0000
24 June 2026	XLON	808.1319	28,942	797.5000	826.0000
25 June 2026	XLON	818.9724	42,411	814.0000	831.5000
26 June 2026	XLON	801.4711	40,766	785.0000	819.0000

The Company intends to cancel the purchased shares.

Schedule of Purchases - Individual Transactions

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation) (which forms part of domestic UK law by virtue of the European Union (Withdrawal) Act 2018, as amended), a full breakdown of the individual trades made by Investec on behalf of the Company as part of the share buyback programme is attached to this announcement.

http://www.rns-pdf.londonstockexchange.com/rns/1593K_1-2026-6-29.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

For further information please contact:

Investor queries

Steve Nightingale, Director of Investor Relations I steve.nightingale@fever-tree.com I +44 (0)7951 849564

Media queries

Oliver Winters, Director of Communications I oliver.winters@fever-tree.com I +44 (0)770 332 9024

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END